GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (FRA:640) » Definitions » Shares Outstanding (EOP)

China Resources Pharmaceutical Group (FRA:640) Shares Outstanding (EOP) : 6,283 Mil (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. China Resources Pharmaceutical Group's shares outstanding for the quarter that ended in Jun. 2024 was 6,283 Mil.

China Resources Pharmaceutical Group's quarterly shares outstanding stayed the same from Dec. 2023 (6,283 Mil) to Jun. 2024 (6,283 Mil).

China Resources Pharmaceutical Group's annual shares outstanding stayed the same from Dec. 2022 (6,283 Mil) to Dec. 2023 (6,283 Mil).


China Resources Pharmaceutical Group Shares Outstanding (EOP) Historical Data

The historical data trend for China Resources Pharmaceutical Group's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Shares Outstanding (EOP) Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,284.51 6,282.51 6,282.51 6,282.51 6,282.51

China Resources Pharmaceutical Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,282.51 6,282.51 6,282.51 6,282.51 6,282.51

Competitive Comparison of China Resources Pharmaceutical Group's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's Shares Outstanding (EOP) falls into.



China Resources Pharmaceutical Group Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


China Resources Pharmaceutical Group  (FRA:640) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


China Resources Pharmaceutical Group Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2023, the medical distribution business accounts for 82.6% of its total revenue. CR Pharma's manufacturing business, 17.8% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.

China Resources Pharmaceutical Group Headlines

No Headlines